Introduction
If you have been searching for a medically sound, doctor-supervised GLP-1 weight loss program in Bangalore, you are certainly not alone. In clinics across the city — from Koramangala and JP Nagar to Whitefield and Indiranagar — more and more patients are asking about GLP-1 injections like Mounjaro (Tirzepatide) and Ozempic (Semaglutide) as a safe, evidence-based alternative to fad diets and crash programmes.
GLP-1 receptor agonists have fundamentally changed how obesity is treated worldwide. But their effectiveness is inseparable from proper medical oversight. This is exactly where a structured, doctor-led programme makes all the difference. At Dr. Tulip’s Obesity & Diabetes Surgery Centre (TODS), we have built one of Bangalore’s most comprehensive GLP-1 weight loss programmes around safety, personalisation, and long-term metabolic health — not quick fixes.
This guide explains what a GLP-1 programme involves, how to assess if you are a suitable candidate, and what sets a high-quality medical programme apart from the rest.
Table of Contents
- What Is a GLP-1 Weight Loss Programme?
- How GLP-1 Medications Work
- Mounjaro vs. Ozempic — A Quick Comparison
- Who Is a Good Candidate?
- What Does the TODS Programme Look Like?
- Why Bangalore Patients Choose TODS
- Risks, Side Effects, and What to Watch For
- Real-World Outcomes: What to Expect
- FAQs
- Local SEO Section
- Doctor Review
- Call to Action
What Is a GLP-1 Weight Loss Programme?
A GLP-1 weight loss programme is a structured medical intervention that uses glucagon-like peptide-1 (GLP-1) receptor agonist medications — such as Semaglutide (Ozempic/Wegovy) or Tirzepatide (Mounjaro) — alongside diet counselling, metabolic monitoring, and regular physician reviews to help patients achieve meaningful, sustained weight loss.
Unlike over-the-counter diet supplements or generic slimming clinics, a proper GLP-1 programme begins with a thorough medical evaluation: blood tests, cardiovascular screening, HbA1c, fasting insulin, thyroid function, liver enzymes, and body composition analysis. The medication dose is then titrated gradually — starting low and moving up only when it is safe and well-tolerated.
The ‘programme’ aspect is critical. GLP-1 medications are powerful tools, but they work best when paired with nutritional guidance, physical activity support, and a physician who understands your metabolic history. Without that structure, patients risk poor dosing, unmanaged side effects, or weight regain once medication stops.
How GLP-1 Medications Work
GLP-1 is a natural gut hormone released after eating. It signals the brain to reduce appetite, slows the rate at which food leaves the stomach (gastric emptying), and improves insulin sensitivity. GLP-1 receptor agonists mimic this hormone — but with a longer duration of action than the body’s own GLP-1.
The result is that patients feel full sooner, eat less, experience fewer cravings — particularly for high-calorie processed foods — and, over time, lose meaningful body weight. In landmark clinical trials, semaglutide (STEP-1, NEJM 2021) produced an average body weight reduction of approximately 14.9% over 68 weeks. Tirzepatide (SURMOUNT-1) produced even greater average reductions — up to 20.9% in some arms of the trial.
These outcomes are comparable to results seen with metabolic surgery in carefully selected patients, making GLP-1 therapy one of the most significant developments in non-surgical obesity medicine in decades.
Mounjaro vs. Ozempic — A Quick Comparison
Both medications belong to the GLP-1 class but differ in mechanism. Ozempic (Semaglutide) is a pure GLP-1 receptor agonist. Mounjaro (Tirzepatide) is a dual GLP-1 and GIP receptor agonist — meaning it activates two metabolic hormone pathways simultaneously.
In head-to-head clinical data, Tirzepatide consistently produces greater average weight loss than Semaglutide, though both are effective and both are available at TODS. Your doctor will recommend the most appropriate option based on your medical profile, metabolic markers, existing conditions, and treatment goals.
Cost is also a practical consideration. As of mid-2026, Mounjaro (Eli Lilly) starts at approximately ₹3,281 per weekly injection in India, while Ozempic (Novo Nordisk) starts at around ₹1,415 per weekly injection. Generic Semaglutide options are also now available in India from approximately ₹325 per weekly injection — though medical supervision remains equally important regardless of the brand prescribed.
Who Is a Good Candidate?
GLP-1 therapy is generally appropriate for adults with a BMI of 27.5 or above (the threshold used for South Asian populations) who also have at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, or fatty liver disease (NAFLD).
Patients with a BMI of 32.5 or above may be candidates even without a comorbidity, depending on clinical assessment. This is determined through a comprehensive consultation — not a quick online form.
GLP-1 medications are not appropriate for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), severe gastrointestinal disease, pancreatitis, or those who are pregnant or planning pregnancy. A full contraindication review is part of every TODS assessment.
What Does the TODS Programme Look Like?
Step 1 is a comprehensive medical assessment: full blood panel, body composition scan, cardiovascular risk profiling, dietary history, and metabolic evaluation by a senior physician. This takes place at our centre, which is easily accessible from South Bangalore areas including JP Nagar, Banashankari, and Jayanagar.
Step 2 is a personalised treatment plan. Based on your assessment, we determine whether Semaglutide or Tirzepatide is more appropriate, what your starting dose should be, and what your titration schedule will look like over the following weeks.
Step 3 is ongoing monitoring. Monthly reviews include weight, blood pressure, blood glucose, side-effect assessment, and dietary adherence. Dosing adjustments are made by the physician — never left to the patient to self-manage without guidance.
Step 4 is long-term planning. We discuss what happens at the end of active therapy — weight maintenance strategies, lifestyle anchoring, and the evidence around medication duration — so that every patient has a realistic roadmap beyond the injection phase.
Why Bangalore Patients Choose TODS
TODS was founded by Dr. Tulip, one of Bangalore’s most respected obesity and metabolic surgery specialists. Unlike clinics that have recently added GLP-1 therapy as a side service, TODS was built around obesity medicine from the ground up. Every aspect of our programme — from diagnostic protocols to follow-up structure — reflects clinical best practice.
Our patients come from across the city: IT professionals from Whitefield and Electronic City who have limited time for follow-ups (we offer flexible scheduling), homemakers from Rajajinagar and Malleshwaram who want a doctor who speaks plainly about treatment, and working professionals from HSR Layout and BTM Layout who need a programme that fits around demanding schedules.
We are not a weight loss spa. We are not a gym with a doctor on call. We are a dedicated obesity medicine centre where every patient is seen, assessed, and managed by qualified physicians committed to evidence-based care.
Risks, Side Effects, and What to Watch For
GLP-1 medications are well tolerated by most patients, particularly when doses are titrated gradually. The most common side effects are gastrointestinal in nature: nausea, vomiting, constipation, or diarrhoea. These are generally mild and transient, and tend to improve after the first few weeks.
Rare but serious considerations include pancreatitis, gallbladder disease, and — in theoretical animal models — thyroid C-cell effects (the clinical relevance in humans is still under study). This is precisely why a proper medical evaluation before starting treatment, and regular monitoring during it, is not optional — it is essential.
At TODS, our doctors provide detailed pre-treatment counselling so that patients know exactly what to expect, when to contact the clinic, and when a symptom warrants early review. Self-medicating with GLP-1 injections purchased online — without evaluation or monitoring — is something we strongly advise against.
Real-World Outcomes: What to Expect
Clinical trial results are an average across large populations. In practice, individual weight loss varies. Most patients in a well-supervised programme can expect 5–15% body weight reduction over 6–12 months, with the higher end of that range more achievable with Tirzepatide in adherent patients.
Equally important are the metabolic benefits: meaningful improvements in HbA1c, blood pressure, lipids, liver fat, and sleep quality often occur well before the most dramatic weight changes. For many patients, these functional improvements are the most personally meaningful outcome of treatment.
We do not guarantee specific weight loss results — no ethical clinic does. What we guarantee is that our programme is built on science, delivered with care, and reviewed continuously by doctors who understand obesity as the complex metabolic condition it is.
Frequently Asked Questions
(Use FAQPage schema markup for these Q&As to target Google’s People Also Ask boxes)
Q: Is GLP-1 therapy available in Bangalore?
A: Yes. Mounjaro (Tirzepatide) and Ozempic (Semaglutide) are both available in Bangalore under doctor supervision. At TODS, we have a structured medical programme for eligible patients.
Q: How much does a GLP-1 programme cost in Bangalore?
A: Costs depend on the medication chosen, dosage, and duration. Mounjaro starts at approximately ₹3,281 per weekly injection and Ozempic from approximately ₹1,415 per week. Generic Semaglutide options are also available from around ₹325 per week. Programme fees are separate and include consultations, monitoring, and follow-up.
Q: Do I need a prescription for Mounjaro or Ozempic?
A: Yes. Both are prescription medications and should only be started after a medical evaluation. Obtaining them without a proper assessment significantly increases the risk of adverse effects.
Q: How long do I need to be on GLP-1 medication?
A: Duration depends on your health goals and response to treatment. Many patients use GLP-1 therapy for 12–24 months. Long-term use is being studied, and your TODS physician will review duration as part of your ongoing plan.
Q: Will I regain weight when I stop?
A: Some weight regain is common after stopping GLP-1 medications, as the medication’s appetite-suppressing effect diminishes. This is why lifestyle changes built during treatment are critical to long-term maintenance. Your TODS programme includes exit planning for this reason.
Q: Is the TODS clinic easily accessible from Koramangala or Whitefield?
A: Yes. TODS is located in South Bangalore and is accessible by major road networks from Koramangala, HSR Layout, JP Nagar, Electronic City, and other areas. We also offer appointment scheduling to minimise wait times.
Doctor Review Section
⚕ Medical Review Notice
This article has been reviewed for clinical accuracy by the medical team at Dr. Tulip’s Obesity & Diabetes Surgery Centre. The information provided is for educational purposes and does not constitute personalised medical advice. Please consult a qualified physician before beginning any weight loss programme.
Reviewed by: Dr. Tulip, MS, FMAS, FIAGES — Senior Bariatric & Metabolic Surgeon, TODS India
